Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide 2.4mg injection) is licensed in Scotland, but that does not automatically mean it is easy to obtain. NHS access north of the border follows different criteria and commissioning decisions than England, and waiting lists through specialist weight-management services can be lengthy. Private prescription routes are open to eligible adults throughout Scotland right now, without waiting for a referral. As a prescription-only medicine, Wegovy requires a clinical assessment before it can be dispensed — a prescriber, not a website form, decides whether it is appropriate for you. More about how Wegovy works as a weight-loss treatment, including what the trial evidence shows for average weight reduction.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy is not straightforwardly available through every GP surgery in Scotland. NHS commissioning decisions for high-cost medicines are made partly at a national level by the Scottish Medicines Consortium (SMC) and partly by individual health boards, which means the picture varies depending on where you live. As a general rule, semaglutide for weight management has been available in Scotland through specialist weight-management services and hospital clinics for qualifying patients, though waiting lists are commonly long and referral criteria are set locally.
It is worth checking NHS Inform Scotland's guidance on diabetes and weight-loss medication for the most current devolved picture, this page is updated when commissioning decisions change and takes roughly thirty seconds to read. The NICE technology appraisal that guides NHS use of semaglutide in England (TA875) specifies a maximum treatment duration of two years, within a specialist multidisciplinary service; Scotland's criteria are set independently and may differ in detail. What stays the same across all four nations is the licensed eligibility threshold: adults with a BMI of 30 or above, or 27 and above with at least one qualifying condition such as high blood pressure, high cholesterol or obstructive sleep apnoea.
If your GP has not raised Wegovy with you, that does not necessarily mean you do not qualify, it may simply mean your health board has not yet made it routinely available in primary care.
No, and this is a common source of confusion. The NHS England phased rollout for tirzepatide (Mounjaro), announced following NICE's appraisal TA1026, applies specifically to England. Scotland runs its own commissioning process, and the cohort-by-cohort BMI and comorbidity thresholds that apply in England do not automatically apply north of the border. If you have been reading about England's rollout expanding to new cohorts, that news does not change what is available through your Scottish health board.
For a fuller picture of how access compares across the four UK nations, the UK-wide Wegovy availability guide on this site covers the key differences in plain terms. Wales follows yet another set of commissioning decisions; availability in Wales is covered separately for readers in that nation.
The practical takeaway for people in Scotland: NHS access exists but is not uniform, and whether you qualify depends on your local health board's current criteria. Contacting your GP surgery directly, or calling 111, is the most reliable way to find out what your health board currently funds.
Yes. Private prescription routes are available throughout Scotland, as they are across the rest of the UK. A GPhC-registered online pharmacy can assess and, where clinically appropriate, prescribe Wegovy for adults who meet the licensed eligibility criteria, with no GP referral and no waiting list. The licensed threshold is a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.
One thing the private route does not change: Wegovy remains a prescription-only medicine, and every order requires a genuine clinical assessment. At nume, that means a GPhC-registered Independent Prescriber reads your consultation the same working day, a real clinician making a considered decision, not an automated screening tool. If approved, treatment is dispatched the same day for free next-working-day DPD delivery. There are no subscription commitments and no hidden fees. Cost is a reasonable question when you are weighing up private treatment; the Wegovy cost guide sets out what private treatment typically includes and what to watch for in headline prices that seem unusually low.
For anyone who wants to explore what private treatment involves before committing, the Wegovy near me page explains the difference between local clinic appointments and fully online pharmacy services, both of which are accessible from anywhere in Scotland.
The clearest path forward depends on your situation. If you think you may qualify for NHS treatment, speak to your GP first, they can tell you what your health board currently commissions and whether a referral to a specialist service is realistic. That conversation costs nothing and takes five minutes. If NHS access is unavailable to you, or you would rather not wait, a regulated private pharmacy offers the same licensed medicine with a same-day clinical review.
Either way, treatment with Wegovy is not a decision to make without clinical input. Semaglutide is a Black Triangle medicine, meaning the MHRA requires additional monitoring of its use post-authorisation. Side effects are real, gastrointestinal symptoms like nausea, constipation and indigestion are the most commonly reported, and a prescriber needs to know your full medical picture before treatment starts. The NHS semaglutide medicine page gives a reliable plain-English overview of what to expect.
Our dedicated Scotland Wegovy guide goes into more detail on health-board-specific access and what the private consultation process looks like for readers based in Scotland. When you are ready to take the next step, speaking to our prescribers is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.